The failure of Novartis's Lp(a) study was foreshadowed by its extended timeline. When events in an outcome-based trial occur slower than modeled, it suggests a mispowered study or misunderstood background factors, almost always leading to a negative result. Amgen's similar issue is a warning sign.
The high-profile failure of a clinically risky $12B acquisition is triggering activism and questioning pharma's M&A strategy. This may push companies to overpay for de-risked, post-Phase III commercial assets rather than take on the clinical development risk of earlier-stage bets, despite the higher price tag.
The DM1 disease target, DMPK RNA, is stuck in the cell nucleus. The failure of Avidity's siRNA-based drug may be due to siRNA's primarily cytoplasmic mechanism. Dyne's drug uses an ASO, a modality that has proven effective against nuclear targets like in SMA, suggesting it could be better suited for this disease.
Contrary to the belief that pharma can acquire any company, their options are highly constrained. Deals depend on finding targets that are willing sellers at the right time and valuation. The final choice is often "who you're able to buy," not just "who you want to buy," after navigating internal consensus.
While biotech is labeled "rate-sensitive," the sector's performance is driven by the overall direction and magnitude of interest rate changes, not small 25 basis point tweaks. The key concern is thematic shifts, like sustained 100+ basis point moves over a year, which fundamentally alter the macro environment for long-duration assets.
Recent HHS appointments signal a return to stability after a period of "chaos" under previous FDA leadership. The industry prefers leaders who act like a "conductor" facilitating scientific discourse, rather than disruptive decision-makers. This predictability is more valuable than any specific policy ideology for long-term planning.
Recent failures in trials for hsCRP and Lp(a) targets highlight a growing challenge in cardiovascular R&D. Existing treatments like statins and GLP-1s have raised the standard of care so high that proving an incremental benefit for a new drug is incredibly difficult, requiring massive, expensive, and often unsuccessful studies.
Royvant's success with its PH-ILD drug is not just about the positive data, but its operational velocity. Announcing the initiation of its Phase 3 study simultaneously with the Phase 2 results showcases a "better and faster than pharma" execution model that compresses timelines and builds investor confidence.
Novartis's DM1 failure joins other challenging neurology acquisitions like AbbVie's Cerevel. Diseases with subjective endpoints are proving exceptionally risky for M&A. Another negative result, such as with Bristol's Karuna deal, could make pharma reluctant to acquire development-stage neuro assets until they are fully de-risked.